Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Dexmedetomidine

If you want to know more about the Dexmedetomidine, the following articles will give you some help. These news is the latest market situation, trend in development, or related tips of the Dexmedetomidine industry. More news about Dexmedetomidine, are being released. Follow us / contact us for more Dexmedetomidine information!
  • Drug Patent & Exclusivity Expiration Report - Week of March 31 2025

    Drug Patent & Exclusivity Expiration Report - Week of March 31 2025

    2025-03-31

    This week, there are 4 drugs in the patent and exclusivity list. They are: - ASTRAZENECA AB's WAINUA (AUTOINJECTOR), containing active ingredient EPLONTERSEN SODIUM - AZURITY PHARMACEUTICALS INC's HORIZANT, containing active ingredient GABAPENTIN ENACARBIL - BIOXCEL THERAPEUTICS INC's IGALMI, containing active ingredient DEXMEDETOMIDINE HYDROCHLORIDE - PHARMAAND GMBH's RUBRACA, containing active ingredient RUCAPARIB CAMSYLATE Read More